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Abstract 
Monodermal teratomas of the ovary can take
the form of carcinoid tumors of which there
are  several  types,  mucinous  carcinoid  being
the least common. Very few cases of primary
mucinous  carcinoid  of  the  ovary  have  been
reported in the literature and the behavior of
these tumors over the long term is unclear. We
describe a case of primary mucinous carcinoid
of the ovary in a 39-year-old woman treated
with unilateral salpingo-oophorectomy, where
a  metastasis  occurred  in  the  contralateral
ovary ten years later. This case demonstrates
that  mucinous  carcinoid  of  the  ovary  can
metastasize  even  after  a  long  interval,  and
careful follow-up of patients, particularly those
treated conservatively, is appropriate. 
Introduction 
Fewer than thirty cases of primary mucin  -
ous carcinoid of the ovary have been described
in the literature and the clinical behavior of
this  tumor  has  not  been  well  defined.
1,2 We
describe  a  patient  treated  by  unilateral
oophorectomy who presented with a metasta-
sis in the contralateral ovary more than ten
years later.
Case Report 
A 39-year-old woman presented with weight
loss and abdominal distention and was found
to have a pelvic-abdominal mass. Her previous
history  included  an  appendectomy  27  years
earlier and a negative laparoscopy four years
previously. At laparotomy there was a 10 cm
mass originating from the left ovary, and a left
salpingo-oophorectomy  was  performed.  The
uterus  and  right  ovary  appeared  normal  at
operation,  as  did  the  peritoneum,  liver,
diaphragm, and lymph nodes. A diagnosis of
mucinous carcinoid of the left ovary was made
after  postoperative  gastroscopy,  computer
tomography (CT) scan, mammography, ultra-
sound scan of the liver, and urine test for the
serotonin metabolite 5-HIAA proved negative.
In  the  light  of  these  negative  findings,  and
given a strong desire on the part of the patient
for children, a decision was made to treat her
conservatively.
The patient was followed up for ten years
but shortly after, now 49 years old, she present-
ed with constipation and abdominal discom-
fort.  A  CT  scan  showed  a  mass  measuring
15¥10 cm originating from the right ovary. A
right salpingo-oophorectomy and partial omen-
tectomy  were  performed;  no  abnormalities
were  seen  on  the  peritoneum,  liver,  or
diaphragm at operation and there was no obvi-
ous lymph node swelling. A histological diag-
nosis  of  metastatic  mucinous  carcinoid  was
made.  Currently,  five  years  after  the  second
laparotomy, the patient remains well.
Pathological findings 
Macroscopic appearances
The first tumor, from the left ovary, weighed
394 g and measured 9.0 cm in maximum diam-
eter (sampled in nine blocks). The cut surface
was partly solid and homogeneous with a light
brown color and partly cystic. The right ovarian
tumor, removed ten years later, was 19 cm in
diameter and weighed 1900 g (sampled in 20
blocks). This lesion was predominantly cystic,
with a solid area of 5 cm in diameter. 
Microscopic appearances 
The  original  tumor  from  the  left  ovary
showed  predominantly  small,  round  glands
lined by cells with globules of intracytoplasmic
mucin, lying in a collagenous stroma (Figure
1A) or floating in lakes of mucin. In most of the
tumor the epithelial cell nuclei were small and
basal with not more than mild atypia (Figure
1B). In some areas, however, the glands were
lined with more obviously atypical cells (Figure
1C). Here the glands lay closer together, some-
times  abutting  on  one  another.  In  one  area
there were smaller glands with some cell nests
and individual signet ring cells. There was no
severe cytological atypia, solid growth of tumor
cells  or  necrosis.  An  occasional  cystic  space
was present lined by goblet cells with some
stratification. Mitotic activity in the more atyp-
ical  areas  reached  10  mitoses  per  10  HPF.
Elsewhere in the tumor the mitotic rate was
lower but varied, with some areas showing 6
mitoses per 10 HPF. 
The metastatic tumor from the right ovary
showed round glands with an epithelial lining
that included goblet cells. Between the goblet
cells  cylindrical  cells  with  granular  eosino  -
philic  cytoplasm  were  present.  Occasionally
there were glands with small basal nuclei with
mild  atypia,  but  in  most  areas  the  glands
showed a moderate epithelial atypia (Figure
2).  In  some  areas  the  glands  lay  closer  to  -
gether,  but  nowhere  was  there  a  confluent
growth  pattern  or  cribriform  growth.  There
were no solid areas. Individual signet ring cells
in the stroma were not a feature of this tumor.
The cysts seen macroscopically were a prom  -
inent feature and were lined by the same cell
population  as  the  small  glands,  often  with
multi  layering  (Figure  2).  Fairly  extensive
areas  of  necrosis  were  present,  involving
glands and stroma and interpreted as infarc-
tion rather than true tumor necrosis. Mitotic
activity was focally brisk, 17 per 10 HPF. In nei-
ther  of  the  specimens  was  there  any  other
tumor  component  (for  example,  struma  or
other carcinoid type or mature teratoma com-
ponent) identified. No vascular or lymphatic
invasion was identified.
Immunohistochemistry 
Epitope retrieval was heat-induced and the
buffer used was tris-EDTA, pH 9. Both tumors
showed positivity for chromogranin (Biogenics
LK2H10, 1;200). In the primary tumor, staining
varied  from  sporadic  cells  in  some  areas  to
staining of several cells in every gland in other
areas.  In  the  metastasis,  almost  all  glands
showed staining, varying from a few cells to
50%  of  the  cells  in  the  gland  (Figure  3A).
Synaptophysin (Dako M0776, 1:400) staining
was positive in occasional cells (<5%) in the
primary  tumor  (Figure  3B),  but  no  positive
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cells were found in the metastasis. NSE (Dako
BBS/NC/V1H14, 1:50) and CD56 (Neomarker
123c3.D5, 1:25) staining were negative. 
Molecular biology 
To determine the relationship between the
two  tumors,  loss  of  heterozygosity  (LOH)
analysis was performed. The area of the pri-
mary tumor showing the most cytological and
architectural atypia was selected for analysis.
Sixteen microsatellite markers on 12 different
chromosomes were investigated for LOH. With
four microsatellite markers on four different
chromosomes, LOH was observed. An identical
pattern of loss in both tumors was found with
two microsatellite markers, D8S133 on chro-
mosome 8p and AFMa086WG9 in intron1 of
the PTEN gene on 10q. In addition, there was
LOH identified only in the later tumor with
markers  D11S419  on  chromosome  11p  and
D13S1307 on 13q. 
Discussion 
Mucinous carcinoid is an unusual tumor in
the ovary and has been described more often
as metastatic from the appendix than as a pri-
mary lesion.
3-11 Distinguishing primary ovarian
carcinoid  from  metastatic  carcinoid  can  be
very difficult. Primary carcinoids of the ovary
are generally unilateral. Metastatic carcinoids
are nearly always bilateral and scattered tumor
deposits are present throughout both ovaries.
3
In the case we describe, the appendix had been
removed  27  years  before  the  first  ovarian
tumor  occurred,  effectively  excluding  the
appendix as the primary. After the initial sur-
gery, extensive investigation failed to reveal
any tumor elsewhere and no other primary has
manifest itself in the following 15 years. 
We regard the second ovarian tumor as a
metastasis, and not as a second primary, on
the grounds of the similar histological picture
and  the  findings  of  the  molecular  biology
analysis.  Immunohistochemical  staining  for
chromogranin  was  positive,  and  there  was
scanty staining for synaptophysin in the first
tumor. These immunohistochemical stains can
support  neuroendocrine  differentiation,  but
are not specific for mucinous carcinoid. The
morphology is also of key importance. The fact
that two identical markers were lost points to
the  tumors  being  the  same  entity.  The  new
abnormalities in the metastatic tumor would
represent further chromosomal abnormalities
acquired during the progression of the tumor.
Our patient did not receive adjuvant chem  o  -
therapy  after  her  second  operation,  because
the  literature  suggests  surgical  resection  of
recurrent  disease  for  ovarian  carcinoid
tumors,
12,13 and to our knowledge there is no
clear literature on management of metastatic
mucinous carcinoid. 
The paucity of cases described in the litera-
ture  means  that  the  behavior  of  ovarian
mucin  ous  carcinoid  is  not  clearly  defined.
Baker et al.
1 described 17 cases that they sub-
divided into three groups, initially character-
ized by them as grade 1, 2, and 3 but ultimate-
ly  classified  as  well-differentiated,  atypical,
and carcinoma arising in mucinous carcinoid,
in an attempt to conform to the terminology
used  in  appendiceal  carcinoid.  They  then
attempted  to  correlate  the  histological  type
with the behavior. These authors observed a
gradation in mitotic activity, cytological atypia,
and architectural abnormality along the spec-
trum of lesions they describe. They comment-
ed that although they found no metastases in
their “well-differentiated’’ or “atypical’’ cate-
Case Report
Figure  1.  (A)  Primary  tumor
(left ovary): small round glands
sometimes floating in lakes of
mucin  typified  the  primary
tumor (hematoxylin and eosin,
100X). (B) Glands with small
minimally atypical basal nuclei
predominated  in  this  tumor
(hematoxylin  and  eosin,
400X). (C) In places there was
moderate  cytological  atypia
and  some  fusing  of  glands
(hematoxylin  and  eosin,
400X). 
Figure  2.  Metastatic  tumor
(right ovary). Glands showing
moderate  cytological  atypia
predominated  in  this  tumor.
Note the cystic spaces lined by
stratified  atypical  epithelium
(inset) (hematoxylin and eosin,
200X).
Figure  3.  Immunohistoche  m  -
istry  in  primary  tumor  and
metastatic  tumor.  (A)  Meta  -
static tumor (right ovary): cells
staining positively for chromo-
granin  were  present  in  most
glands  (200X).  (B)  Primary
tumor  (left  ovary):  scattered
cells  stained  positively  with
synaptophysin, in a gland with
cytological atypia (400X).[page 108] [Rare Tumors 2010; 2:e39]
gories  they  nevertheless  suspect  that  these
lesions have a low malignant potential. Two
cases were categorized as carcinoma arising
in mucinous carcinoid, both more than stage I,
and  were  fatal  within  one  year.  All  other
patients, even within this category, were stage
I and remained well. No cases of late metasta-
sis were observed in this series.
Our case showed areas in the primary tumor
that probably can best be classified as atypical
according to the categorization of Baker et al.,
1
although the bulk of the tumor was well differ-
entiated. The metastasis showed much more
widespread  cytological  atypia;  however,  the
severe cytological atypia, solid growth pattern,
and tumor-type necrosis described by Baker et
al1 in their examples of carcinoma arising in
mucinous  carcinoid  were  not  apparent.  The
tumors we describe are difficult to place exact-
ly in the categories described by Baker et al.,
1
but the atypical histological features coupled
with  the  prolonged  clinical  course  seem  to
match their suggestion of a spectrum of histo-
logical  abnormality  and  clinical  behavior  in
these  lesions.  On  the  basis  of  the  case
described  here  we  suggest  that  any  atypical
architecture or increased mitotic activity, even
focally, signals a need for caution in assessing
prognosis.
Take home messages: 
1. Primary mucinous carcinoid in the ovary
is a rare tumor and should be diagnosed
only after rigorous exclusion of a primary
elsewhere.
2. The  course  of  the  disease  may  be  pro-
longed with metastases after many years.
3. Atypical architecture or increased mitotic
activity,  even  focally,  signals  a  need  for
caution in assessing prognosis.
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Chronic recurrent 
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with cutaneous involvement
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Abstract 
Type  IV  osteolysis  or  Gorham-Stout  syn-
drome  is  a  rare  condition  characterized  by
recurrent vascular tumors that disrupt normal
anatomical  architecture.  Gorham-Stout  syn-
drome is most commonly associated with the
skeletal system with resulting replacement of
bone with scar tissue following tumor regres-
sion.  The  loss  of  entire  bones  has  given
Gorham-Stout syndrome the moniker vanish-
ing  bone  disease.  Natural  progression  of
Gorham-Stout  syndrome  is  characterized  by
spontaneous disease resolution. However, rare
variants of recurrent, progressive, and/or sys-
temic disease have been reported. We present
a patient with a history of recurrent Gorham-
Stout  disease  refractory  to  all  treatment
options considered. In addition to skeletal dis-
ease,  our  patient  had  soft  tissue  and  cuta-
neous involvement, thus reflecting the more
aggressive disease variant. Previous surgical
attempts to control disease had been ineffec-
tive and the patient was referred to us for radi-
ation therapy. Treatment with external beam
radiation therapy resulted in good local control
and symptom palliation, but full disease reso-
lution was never accomplished. In addition to
presentation of this patient, a review of the lit-
erature  on  etiological  hypotheses  and
past/future treatment options was conducted
and is included.
Introduction
Type  IV  osteolysis  or  Gorham-Stout  syn-
drome is a rare variant of idiopathic osteolytic
disease.
1 In 1838 Jackson first described the
disease in an 18-year-old man with a gradually
vanishing  humerus.
2 Later,  in  1955  Gorham
and Stout identified and reported 16 patients
with similar disease.
3 Gorham-Stout syndrome
is characterized by progressive angiomatosis
of venous, capillary, or lymphatic origin.
4-6 The
pathology of Gorham-Stout syndrome is associ-
ated  with  angiomatosis  coupled  with  active
osteolysis resulting in vascular tumor replace-
ment of bone. The osteolysis can be monostot-
ic or polyostotic and has the potential to result
in the physical loss of entire bones – hence the
term “vanishing bone disease.” Involution and
resolution, whether spontaneous or treatment
induced,  will  result  in  replacement  of  the
lesion with connective tissue; thus changing
the underlying anatomy and physiology of the
region.  Often,  presentation  of  Gorham-Stout
syndrome is a consequence of the comprom  -
ised skeletal framework.
1,7 Anatomical malfor-
mations and pathological fractures are often
seen  as  common  symptoms  of  presentation.
Other presenting signs or symptoms are asso-
ciated with underlying inflammation, such as
fatigue and generalized pain.
7 Diagnosis is a
combination of clinical suspicion with support-
ive imaging, but is confirmed by histopatholog-
ical  analysis  of  the  lesions.  Biopsy  always
shows extensive nonmalignant hyperprolifera-
tion of small vessels.
1,5,7
Gorham-Stout Syndrome
Review
Gorham-Stout syndrome has been described
in all anatomical locations and tissue types,
but is seen most commonly in the anatomical
girdles  (pelvic  or  shoulder)  or  in  the  long
bones of the extremities. Rarely, soft tissue or
skin  lesions  are  seen  and  their  presence
reflects an increased severity of disease. One
review noted that only five of the 220 (2.27%)
reported cases of Gorham-Stout syndrome had
cutaneous involvement in their disease.
5When
present,  soft  tissue  lesions  are  reflective  of
involved bone distribution.
5
Patient age ranges have been reported from
one  month  to  75  years,
1 with  children  and
young adults being most commonly afflicted.
To date, there has not been an epidemiologic
correlation with race, gender, or geography.
7-10
Originally, Gorham and Stout postulated the
tumors to be secondary to progressive hem  -
angiomatosis.
3,10 The  etiology  is  largely
unknown but is thought to be multifactorial.
Review of current literature yielded many pos-
sible etiological factors. In summary, Gorham-
Stout  syndrome  is  thought  to  result  from  a
complex  interaction  between  growth  factors,
angiogenic factors, and inflammatory media-
tors.  A  previous  study  identified  histological
markers on the characteristic cells of Gorham-
Stout syndrome that indicate a monocyte line-
age.
11 These so-called Gorham cells (GCs) have
been shown to respond to known osteoclastic
and  angiogenic  factors  resulting  in  disease
specific  pathology.  In  particular,  vascular
endothelial  growth  factor  (VEGF)  subtypes,
platelet-derived  growth  factor  subtypes
(PDGF), and inflammatory cytokines (TGF, IL-
6, and IL-1) lead to increased activity of the
GCs.
11,12 In 2006 Bruch-Graher and colleagues
argued a lymphatic origin of the angiomatosis
leading  to  lesion  formation.
5,10 A  publication
written by Hagendoorn et al. emphasized the
evidence supporting lymphatic vasculature as
the  tissue  of  origin  for  Gorham-Stout  syn-
drome tumors. Hagendoorn et al. found that
the majority of endothelial cells in the lesions
expressed  a  surface  protein  indicative  of
lymph  atics,  lymphatic  vascular  endothelial
hyaluronan receptor-1 (LYVE-1).
4,13 In concord -
ance  with  previously  reported  findings,
Hagendoorn et al. identified high circulating
levels of VEGF and PDGF subtypes.
11,13
The  majority  of  cases  reported  show
spontan  eous  resolution  of  disease  for
unknown reasons.
4,14,15 However, rare cases of
chronic  recurrent  angiomatosis  have  been
reported, many ultimately resulting in death.
Chylothorax and spinal cord compression are
two of the more severe examples of complica-
tions  resulting  from  chronic  disease.
Chylothorax results from occlusion of the large
lymphatic  vessels  in  the  thorax  and  in  turn
leads to fluid collection.
5,10,11 Osseous degener  -
ation of the vertebrae leads to skeletal frame-
work  compromisation  and  spinal  cord  com-
pression.  Prompt  therapeutic  intervention  is
recommended with evidence of lymphatic or
vertebral invasion.
1,7,10,16,17
There is no known cure for Gorham-Stout
syndrome and as such treatment depends on
patient  specific  variables.  Historically,  local
control was the primary therapeutic goal for
recurrent  disease.  Classically,  local  disease
was managed with a combination of surgical
resection  or  radiation  therapy.
10,18-21 Investi  -
gation of the literature indicates radiotherapy
to be the best option to halt disease progres-
sion,  with  reported  results  showing  foci  of
bone  regrowth.
7,10,18-21 Investigation  into  the
pathophysiology  behind  Gorham-Stout  syn-
drome has resulted in an evolution in treat-
ment options targeting proposed pathophysio-
logical pathways. For example, bisphosphonate
therapy has been shown to decrease osteolytic
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